Alan Bao


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.


Alan Bao represents clients in adversarial and in corporate matters. In the adversarial arena, he has extensive experience in the resolution of Chinese-foreign business disputes and in proceedings conducted under the Chinese court system. He has advised clients in connection with regulatory and compliance issues, as well as with intellectual property protection and enforcement matters. Alan also counsels companies in US securities litigation and US bankruptcy proceedings, and conducts FCPA and internal compliance investigations on behalf of his clients.

In the corporate arena, Alan has experience in capital markets, mergers and acquisitions, and other general corporate matters. He represents clients in their Hong Kong initial public offerings (IPOs), as well as in FIE, employment, and IP enforcement matters.



  • Mandarin
  • Taiwanese


Bar Admissions

  • California

Court Admissions

  • US Court of Appeals, District of Central California
  • US District Court, District of Central California
  • Superior Court, District of Central California


  • University of Southern California, J.D.; LL.M.
  • China University of Political Science and Law, LL.B., third-class honors

Professional Activities


  • The People's Supreme Court of People's Republic of China


  • Honorable Samuel Bufford, US Bankruptcy Court, California (Central)


  • Student Bar Association (President), International Economic Law School, China University of Political Science and Law
  • Los Angeles County Bar Association 


  • “Comparative Studies of China's Enterprise Bankruptcy Law and the U.S. Bankruptcy Law,” Norton Journal of Bankruptcy Law and Practice (2010)
  • “On the Validity of Parallel Import,” People's Judicature, China (2003)
  • “The Legal Infrastructure, Judicial Independence and Economic Development,” The Forum for Civil and Commercial Justice, China (2006) (served as article editor and translator) 

Transaction experience:

  • A buyer consortium led by Yunfeng Capital, TF Capital, GIC and management in connection with the acquisition of Cellular Biomedicine Group in a “going private” transaction valued at approximately US$380 million
  • Buyer Group in Going Private Transaction of China XD Plastics
  • Representing the PKU-VMing buyer consortium in a competing going private bid against management for a Chinese biopharmaceutical company Sinovac Biotech Ltd. (NASDAQ: SVA)
  • Representing an A-share listed preclinical research company in its acquisition of a US-based CRO company
  • Represented the buyer consortium in the going private transaction of Zhaopin (NYSE: ZPIN)
  • Represented Goldstone Investment as a member of buyer consortium in the going private transaction of Bona Film (NASDAQ: BONA)      
  • Represented the Meinian buyer consortium in a competing going private bid against management for Chinese healthcare Company iKang Healthcare Group (NASDAQ: KANG)
  • Represented Orient Ruide, a member of the buyer group and also a wholly owned subsidiary of Orient Securities (SSE: 600958) in connection with the merger closing of Taomee (NYSE: TAOM)’s going private transaction
  • Represented iMeigu in its competing going private bid against the founders and management for Dangdang (NYSE: DANG)
  • Represented Chinese hotel chain Homeinns (NASDAQ: HMIN) in US$1.75 billion going private transaction
  • Represented a Chinese PE fund on its acquisition of a U.S. based film, television and music production and distribution company
  • Represented an A share listed company in its outbound acquisition of a U.S. film studio
  • Represented an A share listed company in its outbound acquisition of a Finnish entertainment company
  • Represented Lions Gate Entertainment Corp. on co-financing arrangement with Hunan TV & Broadcast Intermediary Co., for distribution and co-development
  • Advised Lions Gate Entertainment Corp. on various co-production opportunities in China
  • Advised a U.S. film and TV production studio on its China development strategies
  • Advised a U.S. film and entertainment company on its potential theme park development project in China
  • Represented a US pre-clinical and clinical laboratory services company in its acquisition of a leading Chinese laboratory animal supplier
  • Represented a Singapore-based private equity fund in its acquisition of a stake in one of the "Big 4" state-owned asset management companies
  • Advised a global investment management company that acted as a senior lender of certain US real estate investments on its negotiation strategy with mezzanine lenders
  • Advised a US private equity bondholder of a Chinese real estate developer group in its negotiation strategy with other lenders and with the real estate group as part of the group's onshore and offshore restructuring
  • Advised a multinational group on Chinese bankruptcy/restructuring issues related to their onshore subsidiaries
  • Advised a European company on the distressed sale of its China assets